On Nov. 24, 2020, Roche announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental New Drug Application for Xofluza (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis).

Post-exposure prophylaxis with single-dose Xofluza was evaluated in the phase III BLOCKSTONE study, which was recently published in The New England Journal of Medicine.

Xofluza was the first single-dose influenza medicine approved for post-exposure prophylaxis.